Your browser doesn't support javascript.
loading
Impact of variant-level batch effects on identification of genetic risk factors in large sequencing studies.
Wickland, Daniel P; Ren, Yingxue; Sinnwell, Jason P; Reddy, Joseph S; Pottier, Cyril; Sarangi, Vivekananda; Carrasquillo, Minerva M; Ross, Owen A; Younkin, Steven G; Ertekin-Taner, Nilüfer; Rademakers, Rosa; Hudson, Matthew E; Mainzer, Liudmila Sergeevna; Biernacka, Joanna M; Asmann, Yan W.
Affiliation
  • Wickland DP; Division of Computational Biology, Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, Florida, United States of America.
  • Ren Y; National Center for Supercomputing Applications, University of Illinois at Urbana-Champaign, Urbana, Illinois, United States of America.
  • Sinnwell JP; Division of Computational Biology, Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, Florida, United States of America.
  • Reddy JS; Division of Computational Biology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, United States of America.
  • Pottier C; Division of Computational Biology, Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, Florida, United States of America.
  • Sarangi V; Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America.
  • Carrasquillo MM; Division of Computational Biology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, United States of America.
  • Ross OA; Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America.
  • Younkin SG; Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America.
  • Ertekin-Taner N; Department of Clinical Genomics, Mayo Clinic, Jacksonville, Florida, United States of America.
  • Rademakers R; Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America.
  • Hudson ME; Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America.
  • Mainzer LS; Department of Neurology, Mayo Clinic, Jacksonville, Florida, United States of America.
  • Biernacka JM; Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America.
  • Asmann YW; National Center for Supercomputing Applications, University of Illinois at Urbana-Champaign, Urbana, Illinois, United States of America.
PLoS One ; 16(4): e0249305, 2021.
Article in En | MEDLINE | ID: mdl-33861770
ABSTRACT
Genetic studies have shifted to sequencing-based rare variants discovery after decades of success in identifying common disease variants by Genome-Wide Association Studies using Single Nucleotide Polymorphism chips. Sequencing-based studies require large sample sizes for statistical power and therefore often inadvertently introduce batch effects because samples are typically collected, processed, and sequenced at multiple centers. Conventionally, batch effects are first detected and visualized using Principal Components Analysis and then controlled by including batch covariates in the disease association models. For sequencing-based genetic studies, because all variants included in the association analyses have passed sequencing-related quality control measures, this conventional approach treats every variant as equal and ignores the substantial differences still remaining in variant qualities and characteristics such as genotype quality scores, alternative allele fractions (fraction of reads supporting alternative allele at a variant position) and sequencing depths. In the Alzheimer's Disease Sequencing Project (ADSP) exome dataset of 9,904 cases and controls, we discovered hidden variant-level differences between sample batches of three sequencing centers and two exome capture kits. Although sequencing centers were included as a covariate in our association models, we observed differences at the variant level in genotype quality and alternative allele fraction between samples processed by different exome capture kits that significantly impacted both the confidence of variant detection and the identification of disease-associated variants. Furthermore, we found that a subset of top disease-risk variants came exclusively from samples processed by one exome capture kit that was more effective at capturing the alternative alleles compared to the other kit. Our findings highlight the importance of additional variant-level quality control for large sequencing-based genetic studies. More importantly, we demonstrate that automatically filtering out variants with batch differences may lead to false negatives if the batch discordances come largely from quality differences and if the batch-specific variants have better quality.
Subject(s)

Full text: 1 Database: MEDLINE Main subject: Genome-Wide Association Study / High-Throughput Nucleotide Sequencing Type of study: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans / Male Language: En Year: 2021 Type: Article

Full text: 1 Database: MEDLINE Main subject: Genome-Wide Association Study / High-Throughput Nucleotide Sequencing Type of study: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans / Male Language: En Year: 2021 Type: Article